ANGLE liquid biopsy used in German breast cancer study

The company’s Parsortix system was used in harness with a device called CellCelector, a micromanipulator, to isolate individual circulating tumour cells

The company's device has helped researchers glean a greater understanding of breast cancer

ANGLE PLC (LON:AGL, OTCQX:ANPCY) said its liquid biopsy system was used in important work to isolate single circulating tumour cells.

The company’s Parsortix system was used in harness with a device called CellCelector, a micromanipulator.

The idea behind the project, carried out by a team of cancer researchers and clinicians in Duesseldorf, was to assess the “heterogeneity” of the disease.

In layman’s terms, they wanted to know what determined the basis of different strains of the same cancer – in this case breast cancer.

By isolating cancer cells the Duesseldorf team was able to detect varying gene expression between the individual CTCs as well as demonstrating that changes in the patient's HER-2 expression can be detected.

HER-2 advance

Human epidermal growth factor receptor 2, or HER-2, plays an important role in the development of breast cancer.

The detailed results of the research were published in the peer-reviewed journal Cancers.

ANGLE’s chief executive Andrew Newland said:  "This new workflow provides a simple and effective approach to single cell CTC analysis, which is a developing area of research use for the Parsortix system. 

“Investigation of gene expression and HER-2 status in breast cancer will be an important application of Parsortix following FDA [US Food & Drug Administration] clearance."

The shares rose 1% to 71.75p

---adds share price---

Quick facts: ANGLE PLC

Price: 70.5 GBX

Market: AIM
Market Cap: £121.82 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ANGLE PLC named herein, including the promotion by the Company of ANGLE PLC in any Content on the Site, the Company receives from said issuer...



ANGLE CEO reports 'progress across multiple fronts' and talks big new...

ANGLE PLC's (LON:AGL) (OTCQX:ANPCY) Andrew Newland speaks to Proactive to update on progress since the COVID-19 lockdown began. He says a key focus during the period has been on finalising the significant amount of written documentation and analysis for the firm’s imminent submission to the...

on 28/4/20

2 min read